Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Rutger H.T. Koornstra et al.|The Lancet Oncology|2021Cited by 389
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceKatherine R. Singleton, Kris C. Wood, Lorin Crawford et al.|Cell Reports|2017Cited by 109
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Daniil Stroyakovskiy, Corneel Coens et al.|The Lancet Oncology|2021Cited by 72
Persister state-directed transitioning and vulnerability in melanomaHeike Chauvistré, Alexander Roesch, Batool Shannan et al.|Nature Communications|2022Cited by 35
Melanoma Therapeutic Strategies That Select Against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceKatherine R. Singleton, Kris C. Wood, Lorin Crawford et al.|SSRN Electronic Journal|2018Cited by 6